Table 1

Demographics and treatment outcomes of the randomly selected participants from the DISCOVER studies and demographics of the healthy controls used for the biomarker studies

Guselkumab 100 mg q4wGuselkumab 100 mg q8wPlaceboHealthy
n=101n=100n=99n=34
Demographics
 Age, yearsMean (SD)47.4 (10.7)47.3 (11.8)47.7 (11.3)46.6 (11.9)
 Sex, n (%)Female51 (50.5)46 (46.0)49 (49.5)18 (52.9)
Male50 (49.5)54 (54.0)50 (50.5)16 (47.1)
 Race, n (%)White97 (96.0)95 (95.0)94 (94.9)33 (97.1)
 BMIMean (SD)29.5 (5.6)29.8 (6.4)29.7 (6.1)NR
Baseline disease
 Psoriasis disease duration (years)Mean (SD)16.9 (12.8)17.0 (12.6)17.0 (12.3)
 PsA disease duration (years)Mean (SD)7.0 (6.9)5.1 (4.8)7.0 (5.8)
 Body surface area affected by psoriasis (%)Mean (SD)14.9 (18.0)16.8 (21.5)13.3 (17.4)
 PASIMean (SD)10.1 (11.8)9.6 (11.2)7.8 (9.7)
 Swollen joint count (66)Mean (SD)10.9 (7.4)11.8 (8.5)11.4 (6.4)
 Tender joint count (68)Mean (SD)20.3 (13.5)20.9 (13.0)20.5 (14.7)
 EnthesitisNumber (%)68 (67.3)65 (65.0)60 (60.6)
 DactylitisNumber (%)36 (35.6)40 (40.0)36 (36.4)
Baseline medication usage
 Prior anti-TNF useNumber (%)16 (15.8)16 (16.0)16 (16.2)
 No of prior anti-TNF agents113 (12.9)13 (13.0)14 (14.1)
23 (3.0)3 (3.0)2 (2.0)
 Current conventional synthetic DMARDs including MTXNumber (%)68 (67.3)71 (71.0)65 (65.7)
 No of prior DMARDs011 (10.9)11 (11.0)6 (6.1)
155 (54.5)63 (63.0)62 (62.6)
229 (28.7)19 (19.0)23 (23.2)
3+6 (5.9)7 (7.0)8 (8.1)
 Current MTX useNumber (%)59 (58.4)57 (57.0)52 (52.5)
 Current conventional synthetic DMARDs other than MTXNumber (%)9 (8.9)12 (12.0)13 (13.1)
 Current oral corticosteroid use for PsANumber (%)19 (18.8)18 (18.0)22 (22.2)
 Current NSAID use for PsANumber (%)58 (57.4)63 (63.0)65 (65.7)
Clinical efficacy endpointsNumber (%)
 ACR20 response at week24Responder61 (60.4)60 (60.0)26 (26.3)
Non-responder40 (39.6)40 (40.0)73 (73.7)
 ACR50 response at week 24Responder36 (35.6)27 (27.0)12 (12.1)
Non-responder65 (64.4)73 (73.0)87 (87.9)
 IGA Response at week 24Responder49 (70.0)49 (69.0)10 (15.6)
Non-responder21 (30.0)22 (31.0)54 (84.4)
 PASI75 Response at week 24Responder86 (85.2)81 (81.0)20 (20.2)
Non-responder15 (14.9)19 (19.0)79 (79.8)
  • ACR, American College of Rheumatology response criteria; BMI, body mass index; DMARDs, disease modifying anti-rheumatic drugs; IGA, Investigator Global Assessment; MTX, methotrexate; NR, not recorded; NSAID, non-steroidal anti-inflammatory drug; PASI75, Psoriatic Area and Severity Index ≥75%; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; q4w, every 4 weeks; q8w, every 8 weeks; TNF, tumour necrosis factor.